THERAPEUTIC POTENTIAL OF NIMBA-ARAGWADHADI KASHAYA FOR TYPE 2 DIABETES MELLITUS: BRIDGING CLASSICAL AYURVEDIC WISDOM WITH MODERN PHARMACOLOGICAL EVIDENCE - A COMPREHENSIVE REVIEW

Background: Type 2 Diabetes Mellitus (T2DM) affects 589 million adults globally, with 101 million in India. Madhumeha, described in Ayurvedic texts as excessive sweet-tasting urination, correlates with T2DM. Nimba-Aragwadhadi Kashaya, a classical seven-herb formulation, has been prescribed for Prameha management for millennia. Objective: To systematically review clinical and pharmacological evidence supporting Nimba-Aragwadhadi Kashaya’s efficacy in T2DM management. Methods: Comprehensive review of classical Ayurvedic texts (Charaka Samhita, Sushruta Samhita, Sahasrayogam), peer-reviewed research, clinical trials, and pharmacological studies from databases including PubMed, Scopus, Web of Science through January 2025. Results: The formulation comprises Azadirachta indica (Nimba), Cassia fistula (Aragwadha), Alstonia scholaris (Saptaparna), Marsdenia tenacissima (Murva), Holarrhena antidysenterica (Kutaja), Myrica nagi (Somavriksha), and Butea monosperma (Palasha). Individual constituents demonstrate: (1) Enhanced insulin secretion via K_ATP channel modulation; (2) Improved insulin sensitivity through AMPK activation and NF-kB inhibition; (3) Pancreatic β-cell protection via antioxidant mechanisms (SOD increased 28-42%, catalase 32-38%, MDA decreased 39-47%); (4) Anti-inflammatory effects (TNF-α decreased 42%, IL-6 38%, CRP 42-45%); (5) Lipid-lowering properties. Clinical studies demonstrated HbA1c reductions of 0.8-1.5%, improved lipid profiles, and reduced diabetic complications. Bioactive compounds include alkaloids (nimbidin, conessine, berberine-like), flavonoids (quercetin, butein), terpenoids, and polyphenols. Conclusions: Nimba-Aragwadhadi Kashaya demonstrates promising multi-targeted therapeutic potential for T2DM with favorable safety profiles. The polyherbal formulation addresses insulin resistance, β-cell dysfunction, oxidative stress, and inflammation simultaneously. Large-scale randomized controlled trials with standardized preparations are essential for definitive clinical validation and integration into evidence-based diabetes care protocols.